Date Mailed:

OCT 2 2 2001

Anterior #: 09/896, 139

Sheet 1 of 11

FORM 1449* \ 7.
INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USUI Application Number

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: -1645 1724

			U.S. PATENT DOCUMEN	TTS		300/290
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
RIR	4,224,179 (456)	09/23/1980	Schneider			
RR	4,231,877 (457)	11/04/1980	Yamauchi et al.			
RR	4,235,871 (447)	11/25/1980	Papahadjopoulos			
RR	4,247,411 (448)	01/27/1981	Vanlerberghe et al.			
RR	4,394,448 (458)	07/19/1983	Szoka, Jr. et al.			
1513	4,399,216 (459)	08/16/1983	Axel et al.			
RIT	4,522,811 (707)	06/11/1985	Eppstein et al.			
RK	4,616,088 (688)	10/07/1986	Ryono et al.		_	
186	4,636,491 (598)	01/13/1987	Bock et al.			
RR	4,665,193 (706)	05/12/1987	Ryono et al.			
1515	4,668,770 (99)	05/26/1987	Boger et al.			
RR	4,673,567 (460)	06/16/1987	Jizomoto			
195	4,676,980 (461)	06/30/1987	Segal et al.			
188	4,736,866 (474)	04/12/1988	Leder et al.			
RP	4,749,792 (597)	06/07/1988	Natarajan et al.			:
KR	4,753,788 (462)	06/28/1988	Gamble			
RR	4,814,270 (463)	03/21/1989	Piran			
RR	4,816,567 (464)	03/28/1989	Cabilly et al.		·	:
1915	4,870,009 (465)	09/26/1989	Evans et al.			
M	4,880,781 (13)	11/14/1989	Hester, Jr. et al.			
W	4,897,355 (466)	01/30/1990	Eppstein et al.			
तिर	5,010,182 (467)	04/23/1991	Brake et al.		_	
138	5,142,056 (590)	08/25/1992	Kempe et al.			
1315	5,145,684 (846)	09/08/1992	Liversidge et al.			
15/5	5,162,538 (17)	11/10/1992	Voges et al.			
RR	5,175,281 (594)	12/29/1992	McCall et al.			
RT	5,250,565 (444)	10/05/1993	Brooks et al.			

U.S. PATENT DOCUMENTS

EXAMINER	1 Carmin	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conforman and not considered. Include copy of this form for next communication to the Applicant.

6-0003

Date	Mailed:

OCT 2 2 2001

Sheet 2 of 11

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USUI Application Number

09/895,871

H CEN

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 1645

9 200

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING TE IF APPROPRIATE
irr	5,364,934 (468)	11/15/1994	Drayna et al.			
Rus	5,374,652 (446)	12/20/1994	Buzzetti et al.			
VSR .	5,376,542 (469)	12/27/1994	Schlegal		_	
RP	5,387,742 (177)	02/07/1995	Cordell			
156	5,441,870 (189)	08/15/1995	Seubert et al.		_	
19%	5,461,067 (599)	10/24/1995	Norbeck et al.			
RR	5,475,138 (556)	12/12/1995	Pal et al.			
RR	5,481,011 (847)	01/02/1996	Chen et al.			
136	5,482,947 (838)	01/09/1996	Talley et al.	_	_	
RR	5,502,061 (591)	03/26/1996	Hui et al.			
IBS.	5,502,187 (595)	03/26/1996	Ayer et al.			-
V R	5,508,294 (837)	04/16/1996	Vazquez et al.			
Rv?	5,510,349 (853)	04/23/1996	Talley et al.			
RR	5,510,388 (703)	04/23/1996	Vazquez et al.			
ΝÞ	5,516,784 (640)	05/14/1996	Bennett et al.	_	_	
15/S	5,521,219 (850)	05/28/1996	Vazquez et al.			
RR	5,545,640 (642)	08/13/1996	Beautieu et al.			
155	5,593,846 (201)	01/14/1997	Schenk et al.	-		
RR	5,602,175 (542)	02/11/1997	Talley et al.			
RIR	5,602,169 (445)	02/11/1997	Hewawasam et al.			
MR	5,604,102 (202)	02/18/1997	McConlogue et al.			
158	5,610,190 (638)	03/11/1997	Talley et al.		_ · ·	
RR	5,612,486 (185)	03/18/1997	McConlogue et al.		_	
RR	5,625,031 (470)	04/29/1997	Webster et al.	-		
195	5,631,405 (554)	05/20/1997	Pal et al.			
RR	5,639,769 (836)	. 06/17/1997	Vazquez et al.		•	
195	5,648,511 (704)	07/15/1997	Ng et al.			
1965	5,663,200 (18)	09/02/1997	Bold et al.			
RID	5,708,004 (536)	01/13/1998	Talley et al.	T	_	5
			.1	1	1	1

п.	\sim	/	
EXAMINER	Raynuy	DATE CONSIDERED	6-10-0

OCT 2 2 2001

FORM 1449*

INFORMATION DISCLOSURES TATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USU1 Application Number 09/895,871

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 16 5 62 6

0 03
ا ر

and not considered. Include copy of this form for next communication to the Applicant.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance

FORM 1449*	INFORMATION DISCLOSURE	STATEMENT
	<u></u>	مننت

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:
13615.21USU1

Application Nut

09/895,871

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit:

RR	6,051,684 (427)	04/18/2000	McDonald et al.			<u> </u>	
1319	6,060,476 (637)	05/09/2000	Vazquez et al.	-			
RR	6,150,344 (685)	11/21/2000.	Carroll et al.				
ISIS	6,153,652 (191)	11/28/2000	Wu et al.			 	
1712	6,191,166 B1 (50)	02/20/2001	Audia et al.				
प्रर	6,221,670 B1 (355)	04/24/2001	Cordell et al.				
		FO	REIGN PATENT DOCUMEN	ITS			
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION .
				<u> </u> 		YES	NO
RR	0 036776 A2 (471)	09/30/1981	Europe				
RR	0 073 657 B1 (476)	03/09/1983	Europe				
(313	0 117 060 A2 (472)	08/29/1984	Europe				
RR	0 117 058 B1 (473)	08/29/1984	Europe				
1315	0 173 441 A1 (557)	05/03/1986	Europe				
1515	0 209 897 A2 (90)	91/28/1987	Europe				
V217	0 212 903 B1 (100)	03/04/1987	Europe				
198	DE 3610593 A1 (98)	10/01/1987	Germany		_		
RR	0 264 106 B1 (101)	04/20/1988	Europe		_		
િક	DE 3721 855 A1 (93)	09/22/1988	Germany		_		
AR.	0 274 259 A2 (89)	07/13/1988	Europe				
RR	2 203 740 A (544)	10/25/1988	UK		_		
561	2 211 504 A (475)	JÓ7/05/1989	UK .				
RP.	0 320 205 A2 (102)	06/14/1989	Europe		_		-
1513	0 337 714 (8)	10/18/1989	Europe		-		
138	0 362 179 A2 (449)	04/04/1990	Europe		_		
RV	0 372 537 A2 (96)	06/13/1990	Europe				
1515	0 437 729 A2 (21)	971/24/1991	Europe	_			
\ RR	DE 40 03 575 AT	08/08/1991	Germany				
1317	0 609 625 A1 (567)	08/10/1994	Europe				
1215	0 652 009 A1 (709)	05/10/1995	Europe				
1515	7-126286 (97)	05/16/1995	Japan				

EXAMINER

DATE CONSIDERED

6-10-03

748

Date Manet

14800-1:11

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

Docket Number: 13615.21USU1

Application Number:

09/895,871

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: FANG ET AL.
Filing Date: JUNE 29, 2001

Group Art Unit: 1645 1621

R17	WO 87/02986 (551)	65/21/1987	PCT				
RR	WO 87/04349 (10)	07/30/1987	PCT				
RR	WO 87/05330 (454)	99/11/1987	PCT		_		
1513	WO 89/00161 (15)	01/12/1989	PCT ,		-		
RR	WO 89/01488 (12)	02/23/1989	PCT				
RR	WO 89/05859 (453)	06/29/1989	PCT				
126	WO 90/13646 (452)	1//15/1990	PCT		_		
RIS	WO 91/00360 (451)	01/10/1991	PCT				
RR	WO 92/00750 (537)	01/23/1992	PCT				
RY?	WO 92/17490 (14)	10/15/1992	PCT				
RR	WO 92/20373 (455)	11/26/1992	PCT				
RR	WO 93/02057 (11)	02/04/1993	PCT				
20 4	WO 93/08829 (450)	05/13/1993	PCT				
RR X	WO 93/17003 (7)	09/02/1993	PCT	<u> </u>			
1012 %	WO 94/04492 (848)	03/03/1994	PCT				
PRR +	WO 95/06030 (839)	03/02/1995	PCT				
RR #	WQ 97/30072 (22)	08/21/1997	PCT				
RRX	WO 98/22597 (170)	05/28/1998	PCT				
RP u	WO 98/29401 (562)	07/09/1998	PCT				
RŘ 🗸	WQ 98/33795 (546)	08/06/1998	PCT	٠	_	. ::	
RP	WO 98/50342 (550)	11/12/1998	PCT		_		•
RR W	WO 99/41266 (568)	08/19/1999	PCT ·		_		
RR	WO 99/54293 (635)	10/28/1999	PCT		_		
RRX	WO 00/17369 (169)	03/20/2000	PCT . /Later State		1012		୍ବ
1372	WO 00/47618 (364)	08/17/2000	PCT				
RR	WO 00/56335 (314)	09/28/2000	PCT		_		
13/5/	WO 00/61748 (302)	10/19/2000	PCT				
RR	WO 00/69262 (272)	11/23/2000	PCT				
RP	WO 00/77030 (256)	12/21/2000	PCT	. —			
PIT	WO 01/00663 (159)	01/04/2001	PCT				
RR 4	WO 01/00665 A2 (20)	01/04/2001	PCT				

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance

and not considered. Include copy of this form for next communication to the Applicant.

EXAMINER

6-10-03

_ •.	
Date	Mailed

Sheet 6 of 11

I	FORM 1449*	Docket Number:	Application Number:	
	INFORMATION DISCLOSURE STATEMENT	13615.21USU1	09/895,871	
1	IN AN APPLICATION	Applicant: FANG ET AL.		
	(Use several sheets if necessary)	Filing Date: JUNE 29, 2001	Group Art Unit: 1645-162-1	

Г г.	r ·		T	1	· · · · · · · · · · · · · · · · · · ·	_		
* KIS	WO 01/10387 A2 (443)	02/15/2001	PCT					
RIZ	WO 01/19797 A2 (381)	03/22/2001	PCT			<u> </u>		
ARD	WO 01/23533 A2 (289)	04/05/2001	PCT					
· PR	WO 01/29563 A1 (479)	04/26/2001 د	PCT					
RR	WO 01/51659 A2 (790)	07/19/2001	PCT					
	ОТН	ER DOCUMEN	TS (Including Author, Title, Da	nte, Pertinent Pa	ges, Etc.) -			
RR	1 '1		al and Biophysical Research Co		_	15		
	 		mation Based on the β-Secretase	Cleavage Site [439]			
10.0			m, <u>199</u> 8, 41, 3782-3792 w Potent C ₂ -Symmetric HIV-1 P	rotease Inhibito	rs. Use of L-Manna	ric Acid as a Pe	ptidomimetic	
RR	Design and Synthesis of New Potent C ₂ -Symmetric HIV-1 Protease Inhibitors. Use of L-Mannaric Acid as a Peptidomimetic Scaffold [868]							
RR	Amblard et al., J. Med. Chem., 1999, 42:20, pp. 4193-4201							
	Synthesis and Characterization fo Bradykinin B ₂ Receptor Agonists Containing Constrained Dipeptide Mimics [730] Arrowsmith et al., Tetrahedron Letters, 1987, 28:45, pp. 5569-5572							
RR	Amino-Alco	Amino-Alcohol Dipeptide Analogues: A Simple Synthesis of a Versatile Isostere for the Development of Proteinase Inhibitors [584]						
IZR	Highly Disa	Askin et al., The Journal of Organic Chemistry, 1992, 57:10, pp. 2771-2773 Highly Disastrous Alkylations of Chiral Amide Enolates: New Routes to Hydroxyethylene Dipeptide Isostere Inhibitors of HIV-1 Protease [561]						
RR		Balicki et al., Synth. Comm., 1923, 23(22), pp. 3149-3155 Mild and Efficient Conversion of Nitriles to Amides with Basic Urea-Hydrogen Peroxide Adduct [874]						
KIZ	I	Barton, Protective Groups in Organic Chemistry, 1976, Chpt. 2, pp. 43-93 Protection of N-H Bonds and NR ₃ [718]						
KR		Basu et al., Tetrahedron Letters, 1998, 39, pp. 3005-3006 Efficient Transformation of Nitrile into Amide under Mild Condition [881]						
SISV	1	Bennett et al., Synlett, 1993, 9, pp. 703-704 The Synthesis of Novel HIV-Protease Inhibitors via Silica Gel Asisted Addition of Amines to Epoxides [744]						
RR		Berge et al., Journal of Pharmaceutical Sciences, 1/1977, 66:1, pp. 1-19 Pharmaceutical Salts [735]						
RR	· · · · · · · · · · · · · · · · · · ·	Blatt, Organic Syntheses, Collective Vol. 2, pp. 312-315 Heptaldoxime [883]						
RP	Bodendorf et al., The Journal of Biological Chemistry, 2001, 276:15, pp. 12019 - 12023 A Splice Variant of β-Secretase Deficient in the Amyloidogenic Processing of the Amyloid Precursor Protein [493]							

	\sim		`
EXAMINER	Recurry	DATE CONSIDERED	6-10-03

OCT 2 2 2001 5

FORM 1449*

INFORMATION DISCLOSURE SETTEMENT

(Use several sheets if necessary)

IN AN APPLICATION Appl

 Docket Number:
 Application Number:

 13615.21USU1
 09/895,871

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001 Group Art Unit: 1645 (62-)

RR	Bose et al., Synth. Comm., 1997, 27(18), pp. 3119 - 3123 A Facile Hydration of Ntiriles by Dimethyldioxirane [876]
RR	Calderwood et al., <i>Tetrahedron Letters</i> , 1997, 38:7, pp. 1241 - 1244 Organocerium Reactions of Benzamides and Thiobenzamides: A Direct Synthesis of Tertiary Carbinamines [741]
RR	Chen et al., Tetrahedron -Mannaric Acid Letters, 1997, 38:18, pp. 3175 - 3178 A Practical Method for the Preparation of α'-Chloroketones of N-Carbamate Protected-α-Aminoacids [885]
1315	Ciganek, J. Org. Chem., 1992, 57:16, pp. 4521 - 4527 Tertiary Carbinamines by Addition of Organocerium Reagents to Nitriles and Ketimins [721]
1315	Citron et al., Nature, 1992, 360:6405, pp. 672-674 Mutation of the β-amyloid Precursor Protein in Familial Alzheimer's Disease Increases β-Protein Production [722]
RR	Cushman et al., J. Med. Chem., 1997, 40:15, pp. 2323 - 2331 Synthesis of Analogs of 2-Methoxyestradiol with Enhanced Inhibitory Effects on Tubulin Polymerization and Cancer Cell Groth [734]
RR	Deno, et al., J. Am. Chem. Soc., 1970, 92:7, pp. 3700 - 3703 Protonated Cyclopropane Intermediates in the Ractions of Cyclopropanecarboxylic Acids [727]
RR	Diedrich et al., Tetrahedron Letters, 1993, 34:39, pp. 6169-6172 Stereoselective Synthesis of A Hydroxyethylene Dipeptide Isostere [559]
NSIS	Diercks et al., J. Am. Chem. Soc., 1986, 108:11, pp. 3150-3152 Tris(benzocyclobutadieno)benzene, the Triangular [4]Phenylene with a Completely Bond-Fixed Cyclohexatriene Ring: Cobs Catalyzed Synthesis from Hexaethynlbenzene and Thermal Ring Opening to 1,2:5,6:9, 10-Tribenzo-3,4,7,8,11,12 hexadehydro[12]-annulene [728]
RR	Dovey et al., Journal of Neurochemistry, 2001, 76, pp. 173-181 Functional Gamma-Sec]retase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain [396
KK	Dragovich et al., Journal of Medicinal Chemistry, 1929, 42:7, pp. 1203-1212 Structure-Based Desing, Synthesis, and Biological Evaluation of Irreverible Human Rhinovirus 3C Protease Inhibitors [553]
145	Emilien, et al., Neurological Review, 2000, 57, pp. 454-459 Prospects for Pharmacological Intervention in Alzheimer Disease [723]
RR	Felman et al., J. Med. Chem. 1992, 35:7, pp. 1183-190 Synthesis and Antiulcer Activity of Novel 5-(2-Ethenyl Substituted)-3(2H) furanones [724]
RR	Games et al., Letters to Nature, 2/9/1995, 373:6514, pp. 523-527 Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F3-amyloid Precursor Protein [441]
RR	Gao et al., Tetrahedron Letters, 1994, 50:4, pp. 979-988 Asymmetric Hetero Diels-Alder Reaction Catalyzed by Stable and Easily Prepared CAB Catalysts [882]
1513	Getman et al., J. Med. Chem., 1993, 36:2, pp. 288-291 Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere [732]
1317	Ghosh et al., J. Am. Chem. Soc., 2000, -122, pp. 3522-3523 Design of Potent Inhibitors for Human Brain Memapsin 2 β-Secretase). [588]
1315	Ghosh et al., J. Med. Chem., 1993, 36, pp. 2300-2310. Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P3-Ligands [869]

EXAMINER /	Karmy	DATE CONSIDERED	6-10-03

Sheet 8 of 11

13615.21USU1

Application Number

09/895,871

(Use several sheets if necessary)

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 1643

111	
1312	Gould, international Journal of Pharmaceutics, 1986, 33:1-3, pp. 201 - 217 Salt Selection for Basic Drugs [566]
RR	Greene et al., Protective Groups in Organic Synthesis: 2nd Ed., 1991, Chpt. 7, pp. 309-405 Protection for the Amino Group [747]
KR	Greene, Protective Groups in Organic Synthesis, 1981, Chpt. 7, pp.218-287 Protection for the Amino Group [719]
PR	Hardy, Nature Genetics, 1992, 1, pp. 233234 Framing β-Amyloid [725]
1313	Heck, Palladium Reagents in Organic Syntheses, 1985, Chpt. 8.2, pp. 342-365 Carbonylatin of Aromatic Compounds to Acids, Acid Derivatives, Aldehydes and Ketones [870]
ારા	Henning, Organic Synthesis Highlights II, 1995, pp. 251 - 259 A. Synthetic Routes to Different Classes of Natural Products and Analogs Thereof Synthesis of Hydroxyethylene Isoteric Dipeptides [565]
RR	Hon et al., Heterocycles, 1990, 31:10, pp. 17454750 The Studies of Metal Ion Catalyzed Carbon-Hydrogen Insertion of α-Alkoxy-α'-Diazoketones Derived from Mandelic and Lactic Acids [539]
RR	Hong et al., Science, 2000, 290:5489, pp. 150-153 Structure of the Protease Domain of Memapsin 2 (3-Secretase) Complexed with Inhibitor [440]
RR	Hussain et al., Molecular and Cellular Neuroscience, 1999, 14, pp. 419-427 Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase [726]
RR	Kabalka et al., Synth. Comm., 1990, 20(10), pp. 14451451 The Transformation of Nitriles into Amides [875]
RR	Kaldor et al., Bioorganic and Medicinal Chemistry Letters, 1995, 5:7, pp. 721-726 Isophthalic Acid Derivatives: Amino Acid Surrogates for the Inhibition of HIV-1 Protease [587]
ાસર	Kang et al., Nature, 1987, 325:6106, pp. 733736 The Precursor of Alzheimer's Disease Amyloid A4 Portein Resembles a Cell-Surface Receptor [505]
RR	Kitaguchi et al., Nature, 2/11/1988, 331:6156, pp. 530-532 Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity [736]
1515	Klumpp et al., J. Am. Chem. Soc., 1979, 101:23 Lithiation of Cyclopropylcarbinols [871]
RR	Lakouraj et al., Indian Journal of Chemistry, 1999, 38B, pp. 974975 Selective Conversion of Nitriles to Amides by Amberlyst A-26 Supported Hydroperoxide [879]
RIP	Larock, Comprehensive Organic Transformations, 1986, Chpt 4, pp. 972-985 Carboxylic Acids to Amides [555]
SIN	Li et al., Nature, 2000, 405, pp. 689-694 Photoactivated V-secretase Inhibitors Directed to the Active Site Covalently Label Presentlin 1 [24]
RA	Li et al., Nature, 2000, 405:6787, pp. 689694 Photoactivated Gamma-Secretase Inhibitors Directed to the Active Site Covalently Label Presentilin 1. [585]

	 ~	<u> </u>				
EXAMINER	 7	$V_{\mathcal{C}}$	ans	./	DATE CONSIDERED	6-10-03

FORM 1449*

INFORMATION DISCLOSURE TATEMENTS

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 13615.21USU1

Application Number:

09/895,871

Applicant: FANG ET AL.

Filing Date: JUNE 29, 2001

Group Art Unit: 1645 1674

RR	Lin et al., PNAS, 2000, 97:4, pp. 14561460 Human Aspartic Protease Memapsin 2 Cleaves theβ-Amyloid Precursor Protein [687]
1515	Luly et al., Journal of Organic Chemistry, 1987, 52:8, pp. 14871492 A Synthesis of Protected Aminoalkyl Epoxides from Alpha Amino Acids [558]
RR	Luo et al., Nature Neuroscience, 3/2001, 4:3, pp. 231-232 Mice Deficient in BACE1, the Alzheimer's β-secretase, have Normal Phenotype and Abolishedβ-amyloid Generation [210]
RR	March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 3d Ed., pp. 380-381 Aliphatic Nucleophilic Substitution [729]
RR	Martin et al., Tetrahedron Letters, 1998, 39, pp. 15171520 Application of Almez-Mediated Amidation Reactions to Solution Phase Peptide Synthesis [540]
PR	Mashraqui et al., J. Am. Chem. Soc., 1982, 104, pp. 44614465 Cyclophanes. 14. Synthesis, Structure Assignment, and Conformational Properties of [2.2](2,5)Oxazolo- and Thiazolophanes [872]
RK	McLendon et al., <i>The FASEB Journal</i> , 2000, 14:15, pp. 23832386 Cell-Free Assays for Gamma-Secretase Activity [359]
RR	Miyaura et al., Chem. Rev., 1995, 95, pp. 2457-2483 Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds [720]
PR	Moersch et al., Synthesis, 1971, 12, pp. 647-649 The Synthesis of Alpha-Hydroxycarboxylic Acids by Aeration of Lithiated Carboxylic Acids in Tetrahydrofuran Solution [564]
RR	Murahashi et al., J. Org. Chem., 1992, 57:9, pp. 2521-2523 Ruthenium-Catalyzed Hydration of Nitriles and Transformation of δ-Keto Nitriles to Ene-Lactams [877]
(35)	Norman et al., J. Med. Chem., 2000, 43, pp. 42884312 Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine Derivatives and Related Compounds as Neuropeptide Y5 Receptor Antagonists [867]
RR	Owa et al., J. Med. Chem., 1999, 42, pp. 37893799 Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle [866]
156	Pirttila et al., Neuroscience Letter, 1998, 249, pp. 2124 Longitudinal Study of Cerebrospinal Fluid Amyloid Proteins and Apolipoprotein E in Patients with Probable Alzheimer's Disease [738]
1363	Reetz et al., Tetrahedron Letters, 30:40, pp. 54255428 Protective Group Tuning in the Stereoselective Conversion of α-Amino Aldehydes into Aminoalkyl Epoxides [884]
RR	Sabbagh et al., Alzheimer's Disease Review, 1997, 3, 1-19 β-Amyloid and Treatment Opportunities for Alzheimer's Disease [589]
RR	Sakurai et al., Chemical & Pharmaceutical Bulletin, 1993, 41:8, pp. 1378-1386 Studies of HIV-1 Protease Inhibitors, II, Incorporation of Four Types of Hydroxyethylene Dipeptide Isosteres at the Scissile Site of Substrate Sequences [549]
RR	Sakurai et al., Tetrahedron Letters, 1993, 34:10, pp. 5939-5942 A New Synthetic Route for the Gamma-Lactone Precursors of Hydroxyethylene Dipeptide Isosteres [563]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw lin through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC:

(Use several sheets if necessary)

RIZ	Sebti et al., Tetrahedron Letters, 1996, 37:36, pp. 6555-6556 Catalyse Heterogene de L'Hydratation des Nitriles en Amides par le Phosphate Naturel Dope par KF et le Phosphate Trisodique [878]
BR	Selkoe, Nature, 1999, 399:6738, pp. A23-A31 Translating Cell Biology into Therapeutic Advances in Alzheimer's Disease [541]
NR	Selkoe, Neuron, 1991, 6:4, pp. 487-498 The Molecular Pathology of Alzheimer's Disease [742]
RR	Seubert, et al., Nature, 9/1992, 359:6393, pp. 325327 Isolation and Quantification of Soluble Alzheimer's β-peptide from Biological Fluids [503]
RR	Shearman et al., Biochemistry, 2000, 39, pp. 86989704 L-685, 458, an Aspartyl Protease Transition State Mimic, is a Potent Inhibitor of Amyloidβ-Protein Precursor γ-Secretase Activity [394]
RR	Shibata et al., Tetrahedron Letters, 1997, 38:4, pp. 619-620 An Expeditious Synthesis of (2R,3S)-3-tertButoxycarbonylamino-1-isobutylamino-4-phenyl-2-butanol, a Key Building Block of HIV Protease Inhibitors [583]
RR	Sinha, et al., Nature, 12/2/1999, 402:6761, pp. 537540 Purfication and Cloning of Amyloid Precursor Proteinβ-secretase from Human Brain [743]
RR	Smith et al., Advanced Organic Chemistry - Reactions, Mechanisms and Structure, 2001, 5ed., Chpt. 19, pp. 1552-1554 Reduction of Carboxylic Acids and Esters to Alkanese [919]
RR	Snyder et al., J. Am. Chem. Soc., Jan - Jun 1938, pp. 105-111 Organoboron Coimpounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids [873]
RR	Thurkauf et al., J. Med. Chem., 1990, 33, 1452-1458 Synthesis and Anticonvulsant Activity of 1-Phenylcyclohexylamine Analogues [749]
RR	Tucker et al., J. Med. Chem., 1992, 35:14, pp. 2525-2533 A Series of Potent HIV-1 Protease Inhibitors Containing a Hydroxyethyl Secondary Amine Transition State Isostere: Synthesis, Enzyme Inhibition, and Antiviral Activity [731]
1517	Vassar et al., Science, 10/22/1999, 286:5440, pp. 735-741 β-Secretase Cleavage of Alzheimer's Amýloid Precursor Protein by the Transmembrane Aspartic Protease BACE [750]
RR	Vazquez et al., J. of Med. Chem., 1995, 38:4, pp. 581-584 Inhibitors of HIV-1 Protease Containing the Novel and Potent ®-Hydroxyethyl)sulfonamide Isostere [582]
PR	Wang et al., Synlett, 6/2000, 6, pp. 902-904 Preparation of α-Chloroketones by the Chloroacetate Claisen Reaction [886]
RP	Werner et al., Organic Syntheses, 1973, Collective Vol. 5, pp. 273-276 Cyclobutylamine* [752]
er	Wilgus, et al., <i>Tetrahedron Letters</i> , 1995, 36:20, pp. 3469-3472 The Acid-Catalyzed and Uncatalyzed Hydrolysis of Nitriles on Unactivated Alumina [880]
RP	Yan et al., Nature, 12/1999, 402:6761, pp. 533-537 Membrane-anchored Aspartyl Protease with Alzheimer's Diseaseβ-secretase Activity [753]

EXAMINER	RIZ	 DATE CONSIDERED 6-(0-0 > 3.
		was a second and the state of not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation of not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Group Art Unit: 46

Filing Date: JUNE 29, 2001

FORM 1449*
INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION AND APPLICATION



EXAMINER

Rayruf

DATE CONSIDERED

6-10-02